Production & Sales

Dr. Reddy’s to sell neurology branded products to Upsher-Smith Laboratories

Dr. Reddy’s Laboratories has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, pursuant to which Dr. Reddy’s would sell its US and select territory rights for ZEMBRACE SYMTOUCH (sumatriptan injection) 3 mg and TOSYMRA (sumatriptan nasal spray) 10 mg (formerly referred to as “DFN-02”), which are commercialized through its wholly owned subsidiary, Promius Pharma.

Debiopharm, Ipsen extend strategic Decapeptyl partnership for another 15 years

Debiopharm and Ipsen announced renewal of their Decapeptyl agreement, which extends and strengthens their strategic partnership through 2034 for the development, manufacturing and distribution of Decapeptyl across Europe and certain Asian and African markets.

Theramex signs exclusive licensing and supply rights deal with TherapeuticsMD

UK-based Theramex has agreed to acquire exclusive licensing and supply rights from TherapeuticsMD to commercialise BIJUVA (estradiol and progesterone capsules) and IMVEXXY (estradiol vaginal inserts) outside of the US.

Neuraxpharm to launch its first probiotic product in Europe

Neuraxpharm Group, a provider of treatments for central nervous system (CNS) disorders, is set to introduce its first probiotic in the European market.

Chiesi to acquire licensing rights to Santhera’s LHON drug Raxone

Italy-based Chiesi Farmaceutici (Chiesi Group) has agreed to buy the licensing rights of Raxone (idebenone), an approved drug for Leber's hereditary optic neuropathy (LHON) in Europe, from Swiss pharma company Santhera Pharmaceuticals in a deal worth up to CHF105m (£82.5m).

Nektar Therapeutics launches Inheris Biopharma

Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company.

WuXi Biologics signed letter of intent for long-term vaccine manufacturing contract

WuXi Biologics, a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has entered into a strategic partnership letter of intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.

Catalent wraps up $1.2bn acquisition of gene therapy CDMO Paragon

Catalent has wrapped up its $1.2bn acquisition of Maryland-based gene therapy contract development and manufacturing organisation (CDMO) Paragon Bioservices.

Thermo Fisher Scientific to acquire manufacturing site in Cork, Ireland, from GSK

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline plc (NYSE: GSK) for approximately €90 million in cash.